Pointing to the continued circulation and evolution of COVID-19, WHO published a statement on the COVID-19 vaccine antigen composition to respond to variants of the virus.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Orexo and Abera Partner to Develop Nasal Powder Vaccines

By Feliza Mirasol

December 20th 2024

The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.

WHO Activates Global Health Emergency Corp in Response to Mpox

By Susan Haigney

October 29th 2024

WHO and its partners are providing support to countries dealing with mpox outbreaks.

Regulatory Collaboration on Mpox Treatments Summarized in Report

By Susan Haigney

October 25th 2024

The report highlights international regulators’ plans for the development and availability of vaccines to prevent and drugs to treat mpox.

FDA Approves RSV Vaccine

By Susan Haigney

October 23rd 2024

Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at increased risk.

...

25 26 27

About Us

Advertise

Editorial Info

Editorial Advisory Board

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777